StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Mixed but directionally bullish relative to the posted price; the substantial target gap is notable, though the target was lowered.
What happened, with direct paths to the underlying reporting
Wells Fargo lowered its price target for Rapport Therapeutics to $47, still well above the posted price of $25.93, implying roughly 81% upside to the revised target. The target cut tempers the positive implication, and no rationale was provided.
Target: $47
Posted price: $25.93
Analyst firm: Wells Fargo
Analyst: Ben Burnett
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.